If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACC.L Regulatory News (ACC)

  • There is currently no data for ACC

Pulsar update

6 Feb 2020 07:00

RNS Number : 1294C
Access Intelligence PLC
06 February 2020
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Upon the publication of this announcement, the inside information is now considered to be in the public domain for the purposes of MAR.

 

 

 

6th February 2020

ACCESS INTELLIGENCE PLC

Completion of Pulsar Accounting Review

Further to the announcement on 10 December 2019, the Board of Access Intelligence provides the following update following the completion of the review by an external firm of accountants of the accounts of the Pulsar business at closing.

In October 2019, Access Intelligence acquired the Pulsar business (comprising both Fenix Media Limited, which is incorporated in the UK, and Face US, which is incorporated in the US) from Cello Health plc ("Cello"). Following the identification of certain accounting questions on some contracts within Pulsar post acquisition, the Board of Access Intelligence commissioned an accounting review to be undertaken by independent accountants BDO.

Following completion of the BDO review, an adjustment of the previously disclosed unaudited financial results for Pulsar is required. Post this adjustment, for the year to 31 December 2018 Pulsar reported unaudited revenues of £6.8 million, gross profit of £3.8 million and an Adjusted EBITDA loss of £0.7 million. Upon acquisition by Access Intelligence, Pulsar's accounting reference period was amended. For the 11 month period to 30 November 2019, Pulsar would have had reported unaudited revenue of £5.2 million, gross profit of £2.3 million and an Adjusted EBITDA loss of £1.7 million.

Pursuant to the terms of the sale and purchase agreement signed on 2 October 2019 (the "Agreement"), and under the completion accounts reconciliation process agreed by both sides, Cello Health has agreed to pay Access Intelligence a net cash sum of £1.6m reflecting the shortfall in net assets delivered at closing versus the agreed target closing position.

In full and final settlement of any dispute under the Agreement regarding the appropriate valuation of the business, Cello Health has agreed that 4,076,238 of the consideration shares will be sold back to Access Intelligence for £1. As Access Intelligence currently does not have the requisite approvals to acquire these shares, a shareholder's meeting will be convened to obtain the necessary approval for the buy back. Upon completion of the buy back the relevant shares will be cancelled.

The post-acquisition contribution of Pulsar to Access Intelligence's consolidated financial results for the year to 30 November 2019 is expected to be revenue of £0.7 million, gross profit of £0.2 million and an Adjusted EBITDA loss of £0.5 million, prior to any acquisition accounting adjustments. The annual accounts may also be impacted by a potential non-cash write down. This is currently being discussed with the accountants and an update will be provided in due course.

This outcome of the financial analysis has no impact on the rationale for the Pulsar acquisition which is in line with a strategic ambition to strengthen capabilities in social media analysis, audience segmentation and social media marketing evaluation. Recurring revenues with Pulsar are around 70% of total revenue.

Related Party Transaction

Cello is a related party of the Company for the purposes of the AIM Rules by virtue of their status as substantial shareholders holding 10% or more or more of the Company's existing ordinary share capital.

The Board consider, having consulted with the Company's nominated adviser, finnCap, that the settlement with Cello set out above is fair and reasonable insofar as the Company's shareholders are concerned.

Commenting on the resolution of this matter, Joanna Arnold, CEO, said:

"Due to Cello Health's proactive engagement, we are pleased to have reached a swift and satisfactory resolution. The rationale for the acquisition remains unchanged and we look forward to growing the business as part of the Access Intelligence portfolio."

For further information:

Access Intelligence plc 020 3426 4024

Joanna Arnold (CEO) / Mark Fautley (CFO)

 

finnCap Limited (Nominated Adviser and Broker) 020 7220 0500

Corporate Finance - Marc Milmo / Kate Bannatyne / Matthew Radley / Kate Washington

Corporate Broking - Alice Lane / Sunila de Silva

 

About Access Intelligence

 Access Intelligence PLC is a tech innovator, delivering high quality SaaS products that address the fundamental business needs of more than 3,500 global brands in the PR, communications and marketing industries. Listed on AIM, Access Intelligence provides technology that helps organisations understand what's important to their customers and their brand as they navigate a constantly changing world of politics, news and social media. This is alongside the practical tools and information to ensure their communications are relentlessly effective in building awareness, reputation and engagement.

 The expanding portfolio includes Vuelio, the platform that helps organisations make their stories matter; ResponseSource, a network that connects media and influencers to the resources they need, fast; and Pulsar, an audience insights and social listening platform.

 

- ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURSSIEEIESSESE
Date   Source Headline
24th Jun 20157:00 amRNSCompletion of Acquisition
23rd Jun 201510:36 amRNSHolding(s) in Company
16th Jun 201511:53 amRNSAcquisition, Subscription and Directorate Change
28th May 20153:16 pmRNSResult of AGM
28th May 20151:30 pmRNSStatement re. CMA publication
6th May 20158:00 amRNSPosting of Annual Report and Accounts
30th Apr 20157:00 amRNSFinal Results
21st Apr 20151:00 pmRNSDisposal of Willow Starcom Limited
21st Apr 20151:00 pmRNSAcquisition of Willow Starcom
20th Mar 20157:00 amRNSNotice of Results
9th Dec 20143:58 pmRNSDirector/PDMR Shareholding
8th Dec 20147:00 amRNSIssue of CLNS and Trading Update
1st Sep 201411:53 amRNSFurther re: Acquisition of Solcara Limited
26th Aug 201412:26 pmRNSDirector/PDMR Shareholding
21st Jul 20147:00 amRNSDirector Dealings
18th Jul 201410:18 amRNSDirector Dealings
16th Jul 20147:00 amRNSInterim Results
28th Apr 201411:51 amRNSResult of AGM
4th Apr 201411:32 amRNSDirector Dealing
1st Apr 20147:00 amRNSPreliminary Results
11th Mar 20147:00 amRNSConvertible Loan Note Extension
23rd Dec 20137:00 amRNSDirector Dealings
19th Dec 20137:00 amRNSTrading Statement and New CLN Terms
25th Oct 20137:00 amRNSGrant of Options
30th Sep 20137:00 amRNSTrading Update
27th Sep 20137:00 amRNSChange of Registered Office
15th Jul 20137:00 amRNSHalf Yearly Report
9th Jul 20139:30 amRNSNotice of Results
31st May 20131:46 pmRNSTotal Voting Rights
20th May 20137:00 amRNSExercise of Options
22nd Apr 20133:29 pmRNSResult of AGM
19th Mar 20137:00 amRNSChange of Adviser Name
6th Mar 20137:00 amRNSChange of Adviser
5th Mar 20137:00 amRNSFinal Results
20th Dec 20127:00 amRNSTrading Update
10th Dec 20127:30 amRNSDirector/PDMR Shareholding
4th Dec 20127:00 amRNSIssue of Equity
18th Jul 20127:00 amRNSHalf Yearly Report
5th Jul 20125:20 pmRNSNotice of Results
16th Apr 20125:34 pmRNSResult of AGM
21st Mar 20129:09 amRNSHolding(s) in Company
13th Mar 20128:59 amRNSDirector Dealing
9th Mar 20127:00 amRNSDirector/PDMR Shareholding
7th Mar 20127:01 amRNSDirectorate Change
7th Mar 20127:00 amRNSFinal Results
19th Dec 20117:00 amRNSTrading Statement
11th Nov 20117:00 amRNSAppointment of Director
3rd Nov 201112:41 pmRNSDirector/PDMR Shareholding
3rd Oct 20111:22 pmRNSRedemption of Loan Notes
23rd Sep 20117:00 amRNSTotal Voting Rights and Directors' Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.